DoD Traumatic Brain Injury and Psychological Health, Translational Research Award | W81XWH 22 TBIPHRP TRA

Opportunity Information: Apply for W81XWH 22 TBIPHRP TRA

The DoD Traumatic Brain Injury and Psychological Health, Translational Research Award (FY22 TBIPHRP TRA; Funding Opportunity Number W81XWH-22-TBIPHRP-TRA) is a Department of Defense research funding mechanism designed to push promising traumatic brain injury (TBI) and psychological health findings closer to real-world clinical use. The core purpose is to accelerate translation of strong scientific ideas into tangible clinical applications such as healthcare products, enabling technologies, and evidence-based clinical practice guidelines. A key point in how this program defines translation is that it is not treated as a simple one-direction path from laboratory discovery to patient care. Instead, proposals are expected to reflect an iterative, two-way exchange where clinical observations inform basic research and basic research insights refine clinical approaches. Because of this emphasis on actionable progress, applications must be grounded in preliminary and/or published data that justify why the approach is ready for translational advancement.

The program supports a wide range of translational work, including preclinical studies and clinical research that involves human subjects and/or human anatomical substances. It can also fund ancillary studies linked to ongoing or completed clinical trials, as well as projects specifically aimed at improving how future clinical trials should be designed. This includes research that strengthens feasibility, improves outcome measures, refines intervention protocols, or addresses other practical barriers that commonly prevent promising TBI or psychological health concepts from successfully moving into clinical testing or adoption.

If applicants propose animal models, the announcement signals a clear preference for models that are explicitly tied to clinical realities. In particular, it encourages pairing clinical populations with animal models to validate clinical relevance and to help develop better prevention, assessment, and treatment solutions. Animal work must be justified with literature support and must align clearly with the human condition being targeted; in other words, the model should be chosen because it meaningfully reflects the clinical problem rather than because it is convenient or traditional in the field.

A notable feature of the award is that it can include a pilot or exploratory clinical trial, but only as one component of a broader translational research plan. Limited clinical testing is permitted when it is needed to establish feasibility, refine an intervention or device, or generate critical information that guides the next translational step. However, the pilot portion must remain small and cannot dominate the overall scope described in the Statement of Work. The program explicitly does not support large-scale clinical trials under this mechanism. Proposals that are essentially a full clinical trial, or that consist entirely of one pilot trial or multiple pilot trials, may be administratively withdrawn because they fall outside the intended purpose of this award. Applicants whose main goal is to conduct clinical trials are directed instead to other TBIPHRP opportunities such as the FY22 Clinical Trial Award (W81XWH-22-S-TBIPH1) or the FY22 Focused Program Award (W81XWH-22-S-TBIPH2).

For projects that do include a pilot or exploratory clinical trial component, the opportunity allows flexibility in trial methodology, including alternatives to traditional randomized clinical trials, as long as the design fits the study objective. These trial-inclusive applications come with additional submission requirements and are reviewed using extra criteria. There are also compliance requirements tied to human subjects protections: funded trials must publicly post the Institutional Review Board (IRB)-approved informed consent form used to enroll participants, consistent with federal requirements in 32 CFR 219. The award cannot be used for studies that require an Exception From Informed Consent (EFIC), meaning research that would enroll participants without standard informed consent is not allowable under this mechanism.

Administratively, this is a discretionary DoD opportunity administered through the Department of Defense, Department of the Army, USAMRAA, and it uses grant and/or cooperative agreement instruments under CFDA 12.420. Eligibility is listed as unrestricted (open to entity types broadly, subject to any specific clarifications in the full announcement). The posting indicates an anticipated number of awards of about 10. The original FY22 timeline listed a creation date of July 15, 2022, with an original closing date of September 14, 2022, reflecting that this was a specific fiscal year call focused on moving well-supported TBI and psychological health research toward practical clinical impact.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Traumatic Brain Injury and Psychological Health, Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jul 15, 2022.
• Applicants must submit their applications by Sep 14, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 10 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 TBIPHRP TRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: